Atil Kargi, MD
Endocrinology, Diabetes & Metabolism · Chapel Hill, NCNPI 1902918949
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $96,372 of the $149,382 with a category attached, or 64.5%. 14 manufacturers reported payments, led by Corcept Therapeutics at 36.9% of the total. 2025 is the largest year on record at $84,148, more than ten times the $741 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $883.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$55K
- Recordati_rare_diseases_inc.$53K
- Novo Nordisk$15K
- Chiesi USA, Inc.$14K
- Xeris Pharmaceuticals, Inc.$6K
- Ascendis Pharma Endocrinology Inc$2K
- plus $3K from 8 others
Across 59 payments — averaging $518.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Corcept Therapeutics$24K
- Novo Nordisk AS$6K
What the payments were for
- Consulting fees$34,30823%
- Speaking & faculty fees$96,37265%
- Travel & lodging$12,2618%
- Food & beverage$6,2474%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 66 | $55,178 |
| Recordati_rare_diseases_inc. | 36 | $53,336 |
| Novo Nordisk | 24 | $15,299 |
| Chiesi USA, Inc. | 14 | $13,883 |
| Xeris Pharmaceuticals, Inc. | 12 | $6,228 |
| Ascendis Pharma Endocrinology Inc | 1 | $2,132 |
| Ipsen Biopharmaceuticals, Inc | 2 | $1,470 |
| Amgen | 1 | $1,260 |
| Pfizer | 8 | $188 |
| Strongbridge US Inc. | 1 | $137 |
| Shire North American Group Inc | 1 | $119 |
| Amryt Pharma Holdings Ltd | 1 | $82 |
| Radius Health, Inc. | 1 | $51 |
| Novartis | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$53,987
- ISTURISA$46,094
- MYCAPSSA$13,631
- Sogroya$6,794
- RECORLEV$5,912
- Norditropin$5,075
- SKYTROFA$2,132
- SOMATULINE DEPOT$1,420
- TEPEZZA$1,260
- KEVEYIS$137
- GVOKE HYPOPEN$122
How this compares
$149,382 in reported general payments places this provider in the 90th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SomavertPegvisomant | 13 | $180,105 |
| Cabergoline | 22 | $2,328 |
| Testosterone | 15 | $1,253 |
| Hydrocortisone | 39 | $1,083 |
| Testosterone Cypionate | 23 | $453 |
| Levothyroxine Sodium | 34 | $381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerSomavert | $188 | $180,10513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Chapel Hill
- John BuseChapel Hill$460K
- Klara KleinChapel Hill$73K
- Sadia EjazChapel Hill$19K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.